companydata.dkcompanydata.dk

Ascendis Pharma Endocrinology Division A/S: Financial statements 2015

CVR: 32323537

Source: annual report 2015, Danish Business Authority

01/01/2015 – 31/12/2015

Ascendis Pharma Endocrinology Division A/S (CVR 32323537) has filed annual accounts for 2015. In 2015, the company reported a gross profit of EUR -28,800,471 and a net result of EUR -29,557,717 compared with EUR -11,532,115 the year before. Equity in the 2015 report amounted to EUR -44,255,995.

Gross Profit
EUR -28,800,471
Profit/Loss
EUR -29,557,717
Equity
EUR -44,255,995
Total Assets
EUR 5,373,697

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2015--28.8M EUR-29.6M EUR-44.3M EUR-
2014--11.2M EUR-11.5M EUR-14.7M EUR-
2013--46.2M-47.3M-36.9M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Ascendis Pharma Endocrinology Division A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2015

Ascendis Pharma Endocrinology Division A/S: The 2014 annual report is outMay 13, 2015

Ascendis Pharma Endocrinology Division A/S has published its annual report for 2014. Gross profit came to DKK -11,220,985, and the net result was DKK -11,532,115.

About Ascendis Pharma Endocrinology Division A/S

Ascendis Pharma Endocrinology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S and ACP 30.06.2012 2 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported revenue of EUR 140,817,000 and a net result of EUR -38,806,000 compared with EUR -121,118,000 the year before. Equity in the 2025 report amounted to EUR -935,650,000.

Source: annual report 2025, Danish Business Authority